Mirae Asset Global Investments Co. Ltd. Acquires 254,475 Shares of Novo Nordisk A/S (NYSE:NVO)

Mirae Asset Global Investments Co. Ltd. boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 53.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 729,965 shares of the company’s stock after buying an additional 254,475 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Novo Nordisk A/S were worth $63,183,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in NVO. AQR Capital Management LLC increased its position in Novo Nordisk A/S by 110.5% in the 2nd quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock worth $2,450,000 after buying an additional 9,012 shares during the period. Mather Group LLC. grew its holdings in shares of Novo Nordisk A/S by 4.3% during the 3rd quarter. Mather Group LLC. now owns 5,835 shares of the company’s stock worth $695,000 after purchasing an additional 243 shares in the last quarter. Aprio Wealth Management LLC grew its holdings in shares of Novo Nordisk A/S by 4.7% during the 3rd quarter. Aprio Wealth Management LLC now owns 5,148 shares of the company’s stock worth $613,000 after purchasing an additional 230 shares in the last quarter. Tealwood Asset Management Inc. grew its holdings in shares of Novo Nordisk A/S by 0.8% during the 3rd quarter. Tealwood Asset Management Inc. now owns 14,116 shares of the company’s stock worth $1,681,000 after purchasing an additional 116 shares in the last quarter. Finally, Park Place Capital Corp acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $119,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $82.60 on Wednesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a market cap of $370.65 billion, a price-to-earnings ratio of 26.73, a P/E/G ratio of 0.93 and a beta of 0.45. The stock’s fifty day simple moving average is $93.12 and its 200 day simple moving average is $112.54. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 86.32% and a net margin of 35.03%. On average, analysts expect that Novo Nordisk A/S will post 3.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on NVO shares. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.